COMMUNIQUÉS West-GlobeNewswire

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
07/01/2019
– Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets – – Lead Program, IMU-838, an Orally Available, [...]
FIT Biotech Oy: Changes in FIT Biotech's Board of Directors
07/01/2019
FIT Biotech Oy Company release 7.1.2019 at 9:55 EET Changes in FIT Biotech's Board of Directors FIT Biotech Oy's ("Company", FITBIO: FN Finland) Chairman of the Board of Directors, Doctor Chitra Bharucha has resigned [...]
Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
07/01/2019
Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs Companies select two clinical-stage bispecific antibodies for ongoing collaboration Sanofi able to independently [...]
Sanofi et Regeneron restructurent leur collaboration de recherche et développement en immuno-oncologie
07/01/2019
Sanofi et Regeneron restructurent leur collaboration de recherche et développement en immuno-oncologie Les deux entreprises retiennent deux anticorps bispécifiques au stade clinique pour la poursuite de leur [...]
Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference
07/01/2019
LONDON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37 th Annual JP Morgan [...]
Saniona completes treatment in Phase 2a Prader-Willi syndrome trial and initiates open label extension study
07/01/2019
PRESS RELEASE January 7, 2019 Saniona (OMX: SANION), a biotech company focused on CNS and eating disorders, today announced that it has completed the 3-month treatment period in adolescent patients in the second part of [...]
Galapagos starts first Phase 1 trial with Toledo compound
07/01/2019
Novel target class with dual action in inflammatory disorders Discovered and validated on Galapagos' target discovery platform Fully owned and proprietary Mechelen, Belgium; 7 January 2019, 7.30 CET - Galapagos NV ( [...]
Irina Maligina: Changes in the Board of Olmafarm, the main shareholder of Olainfarm, are illegal and will not affect the work of JSC Olainfarm
07/01/2019
Commenting on the recently registered changes in the Board of JSC Olainfarm's largest shareholder – SIA Olmafarm, the Deputy Chairman of the Supervisory Board of JSC Olainfarm, Irina Maligina, informs of the following: [...]
Basilea reports strong, higher than expected preliminary revenue of CHF 133 million for financial year 2018
07/01/2019
Basel, Switzerland, January 07, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the unaudited preliminary revenue for the financial year 2018. Total revenue is expected to increase by 31% over 2017 to [...]
Biocartis Group NV: Biocartis Announces Achieving its 2018 Key Business Objectives
07/01/2019
PRESS RELEASE: REGULATED INFORMATION - INSIDE INFORMATION 7 January 2019, 07:01 CET Biocartis Announces Achieving its 2018 Key Business Objectives Mechelen, Belgium, 7 January 2019 - Biocartis Group NV (the 'Company' or [...]
VALNEVA Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate
07/01/2019
Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate Phase 1 interim results showed an excellent immunogenicity profile after a single-shot vaccination and an acceptable safety profile [...]
VALNEVA annonce des résultats intermédiaires de Phase 1 positifs pour son candidat vaccin contre le Chikungunya
07/01/2019
Valneva annonce des résultats intermédiaires de Phase 1 positifs pour son candidat vaccin contre le Chikungunya Les résultats intermédiaires de Phase 1 ont montré un excellent profil d'immunogénicité après une seule [...]
Idorsia initiates a multiple-dose efficacy and safety study with cenerimod for the treatment of systemic lupus erythematosus
07/01/2019
Allschwil, Switzerland - January 7, 2019 Idorsia Ltd (SIX: IDIA) today announced that the first patient has been enrolled into a multiple-dose study to evaluate the efficacy and safety of cenerimod, a selective S1P 1 [...]
Biocartis Group NV: Biocartis and Nichirei Bioscience Announce Commercialization Collaboration for Japanese Market
07/01/2019
PRESS RELEASE 7 January 2019, 07:00 CET Biocartis and Nichirei Bioscience Announce Commercialization Collaboration for Japanese Market Mechelen, Belgium, 7 January 2019 - Biocartis Group NV (the 'Company' or 'Biocartis [...]
Addex Trading Update: Completes 2018 with Strong Cash Position
07/01/2019
Geneva, Switzerland, 7th January 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has completed the year 2018 with [...]
Innate Pharma : Upcoming investor conferences
07/01/2019
UPCOMING INVESTOR CONFERENCES Marseille, France, January 7, 2019, 7:00 AM CET Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor [...]
Innate Pharma : Prochains rendez-vous investisseurs
07/01/2019
PROCHAINS RENDEZ-VOUS INVESTISSEURS Marseille, le 7 janvier 2019, 7h00 CET Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce aujourd’hui qu’elle sera présente aux événements investisseurs suivants : LifeSci [...]
Xenon Pharmaceuticals Outlines 2019 Key Milestones
07/01/2019
Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 BURNABY, British Columbia, Jan. 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals [...]
Adverum Biotechnologies Provides 2019 Outlook
07/01/2019
Advancing Novel Gene Therapy ADVM-022 for Wet AMD in OPTIC Phase 1 Clinical Trial MENLO PARK, Calif., Jan. 06, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company [...]

Pages